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Abstract
Objective—To investigate the association between Chlamydia trachomatis (CT) infection 
seropositivity and gastroschisis.
Study Design—In this case-control study we enrolled pregnant women either prenatally 
diagnosed with gastroschisis (cases, n=33) or with a normal ultrasound (controls, n=66). Both 
groups attended the University of Utah's Maternal Fetal Medicine Diagnostic Center for their 
diagnostic ultrasound or because of a community obstetrician referral. Participants completed a 
structured interview on potential risk factors. Anti-CT IgG1 and IgG3 were measured by a CT 
elementary body ELISA.
Result—Median age at sexual debut was lower and reported sexual partner number higher in 
cases compared to controls. Risk factors for gastroschisis included having ≥3 sexual partners 
(OR=3.3, 95% CI 1.2, 9.4), change in partner from the previous pregnancy (OR=3.6, 95% CI 0.9, 
13.9), and anti-CT IgG3 seropositivity (age-adjusted OR=3.9, 95% CI: 1.1, 13.2).
Conclusion—Anti-CT IgG3 seropositivity was associated with greater than a 3-fold risk for 
gastroschisis.
Introduction
The increasing prevalence of gastroschisis, a congenital defect of the abdominal wall, has 
been documented over the past several decades in the U.S.1 and around the world.2-6 In the 
U.S., the greatest increase is observed among young women, especially those less than 20 
years of age.1 The cause for this increase and for the dramatic difference by maternal age are 
unknown. The rapidity of the increase suggests that environmental factors play a role. A 
study from the National Birth Defects Prevention Study reported that women delivering an 
infant with gastroschisis were four times more likely to report a genitourinary (GU) 
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infection (i.e., urinary and sexually transmitted infections [STIs]) during the 
periconceptional period than control mothers.7 That study also suggested a specific role of 
Chlamydia trachomatis (CT) infection, which accounted for 43% of GU reported infections 
among case mothers compared to 18% among controls. GU infections were also 
disproportionately more frequent in women <25 years of age. Two additional studies 
reported an association between periconceptional GU infection and risk for gastroschisis.8,9 
Several factors suggest that CT infection should be further investigated as a potential risk 
factor for gastroschisis: 1) it is the most prevalent sexually transmitted bacterial infection; 2) 
prevalence is highest in women aged 15-24 years, and remains high despite a national 
chlamydia control program;10 and 3) the rising rate of CT infection among young women 
has paralleled the increasing prevalence of gastroschisis.
However, investigating CT infection as a risk factor for gastroschisis is challenging, for 
several reasons: 1) subclinical CT infections are frequent (up to 75% of CT-infected women 
are asymptomatic11) which makes using maternal self-report as a marker for CT exposure 
less ideal due to the potential exposure misclassification, and 2) CT infections may resolve 
spontaneously (i.e., without treatment) and therefore a negative CT test (i.e., nucleic acid 
amplification test – NAAT) at a prenatal visit does not rule out a prior periconceptional CT 
exposure.12 Hence, more objective and sensitive approaches are needed to evaluate CT 
exposure. One such proposed measure is a CT-specific antibody response. Geisler et al.13 
recently reported that IgG1 and IgG3, detected by a CT elementary body (EB) ELISA, 
comprised the predominant anti-CT serum antibody response, and the seropositivity rate 
detected by CT EB ELISA was higher than a commercial CT ELISA (Medac). Our primary 
objective was to evaluate the association between gastroschisis and CT seropositivity, which 
was performed using the CT EB ELISA. Secondary objectives included: 1) assess study 
participation rates of pregnant women prenatally diagnosed with and without gastroschisis; 
2) determine the utility of medical record review in documenting prenatal STI screening; 
and 3) evaluate associations of sexual history with gastroschisis.
Methods
Participant Recruitment
Because of the rarity of gastroschisis, we used a case-control design to address the study 
objectives. Pregnant women were recruited from the Maternal-Fetal Diagnostic Center 
(MFDC) at the University of Utah hospital either at the time of their routine diagnostic 
ultrasound (i.e., 18-20 weeks gestation) or referred from the University's obstetric clinics, 
the Teen Mother Child Program, and community obstetricians and midwives. For some case 
women, an ultrasound confirmation of gastroschisis occurred later in the second trimester, 
but the reason was not known. Study coordinators from the Obstetrics and Gynecology 
Research Network (OGRN), trained to sensitively approach women with abnormal 
ultrasound findings, identified potentially eligible pregnant women prenatally diagnosed 
with gastroschisis (cases) and approached them during their visit to the MFDC to provide 
information about the study. Those who desired to participate provided written informed 
consent.
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For each enrolled case, two eligible control women attending the MFDC for any reason with 
a normal ultrasound were matched by gestational age (+/- one week), recruited and 
consented. Approximately 40% of babies born with gastroschisis are delivered to women 
<20 years of age.1 This study did not restrict participation by maternal age. For unmarried 
women ≤17 years of age, parental consent was required for participation. Women were not 
eligible if they did not speak or understand English or Spanish. The study was approved by 
the Institutional Review Board of the University of Utah.
Data Collection and Testing
After obtaining consent, the study coordinator administered a questionnaire in English or 
Spanish that focused on demographics, previous pregnancies and change in partners, 
selected exposures (infections, fevers, tobacco use, medications, and illicit drug use), and 
sexual history. Questions about previous pregnancy history, current pregnancy information, 
and maternal exposures were taken from the National Birth Defect Prevention Study's 
questionnaire (used since 1997) and questions related to sexual history and behavior were 
taken from the validated National Health and Nutrition Examination Survey. Women were 
also asked to sign a release for their prenatal medical records, which were reviewed to 
determine if screening for STIs was performed at the first prenatal visit.
The study coordinator obtained blood from participants after completion of the 
questionnaire. Each participant's interview and samples were assigned a unique study ID 
number. Urine was tested on the first 33 enrollees at the Utah State Laboratory at the Utah 
Department of Health for evidence of active CT and/or gonococcal infection using the 
highly sensitive NAAT (APTIMA Combo 2 assay (Gen-Probe, San Diego, CA).14 The urine 
NAAT screen was discontinued since we were not able to detect active CT infections at the 
time of enrollment (third trimester) among the first 33% participants. This suggests that 
subclinical periconceptional CT infections either cleared or if clinically diagnosed, were 
treated with antibiotics. Serum was extracted from blood and stored in -80° freezers until 
testing. Participants were also asked to provide written consent and permission for blood 
DNA storage for future genetic studies.
Anti-CT Antibody Detection
At first, we measured serum anti-CT IgG antibodies using the commercially available 
SeroELISA Chlamydia IgG kit (Savyon Diagnostics, Israel) per the manufacturer's 
recommendations. However, after testing the initial 16 cases and 28 controls, only one case 
was IgG seropositive, one case had equivocal results, and no controls were seropositive. The 
sensitivity of this assay was concerning. We switched to the CT EB ELISA, an assay in 
which Geisler et al.13 had reported detection of >15% more CT infections than the 
commercially available Medac anti-CT IgG antibody assay. These 44 samples were retested 
with the additional samples (n=55) using the methodology described below. Laboratory 
testing was conducted without knowledge of case or control status.
Formalin-fixed, density gradient purified EBs of CT serovars D, F and J obtained from the 
University of Washington were used as antigens in the EB-ELISA. Working in collaboration 
with Dr. Geisler from the University of Alabama at Birmingham, we established an EB 
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ELISA using methodology similar to those he published.13 Briefly, density gradient purified 
EBs were fixed overnight at 4°C in 10 mM phosphate-buffered saline (PBS) containing 
0.2% formalin. After fixation, EBs were washed once with PBS and re-suspended in PBS 
with 0.02% formalin. Equal volumes of each serovar (2 mg/mL) were combined to make a 
mixture of serovars D, F, and J and used to coat 96–well Immunlon 2 HB U-bottoms plates 
(Thermo Scientific, 2 μg EB/well). Detection of CT-specific antibodies in sera was 
performed with alkaline phosphatase–labeled anti-human IgG monoclonal antibodies (anti-
IgG1 [a pool of clones 4E3, Southern Biotech; and HP6069; Cal Biochem], anti-IgG3 [clone 
HP6050; Southern Biotech]) and Sigma Fast p-nitrophenyl phosphate substrate (1 mg/mL; 
Sigma). The optical density (OD) of the reactions was measured at 405 nm using 
SPECTRAmax PLUS 384 plate reader and analyzed with SoftMax® Pro 4.8 software. To 
establish cutoff values for positive IgG1 and IgG3 responses, sera were collected from 10 
low-risk volunteers (negative controls) and samples from five women with confirmed active 
genital CT infection detected in urine or cervical swab by NAAT (positive controls). 
Samples were diluted 1:32 in ELISA buffer (2% BSA, 0.05 M Tris base, 0.15 M NaCl, 
pH=7.2-7.5) and plated in triplicates onto blocked EB-coated plates. After incubation, plates 
were extensively washed and probed with either anti-CT IgG1 or IgG3 monoclonal 
antibodies. Mean OD405 readings for low-risk samples and 3 standard deviations were 
considered as the cutoff point for positive responses (seropositivity: IgG1≥0.1, IgG3≥0.08). 
OD405 readings for all positive control samples were far above IgG1 and IgG3 cutoff values. 
A positive control sample and negative control sample were used as internal controls in all 
plates on which participant sera were tested. The reported serologic responses of all 
participants represent the mean of triplicate determinations of 1:32 diluted serum for each 
IgG subclass response.
Statistical Analyses
Descriptive statistics were used to compare frequencies of self-reported data. Associations 
of participant characteristics and seropositivity with gastroschisis were evaluated with the 
Chi-squared test or Fisher's exact test (cell size <5) and nonparametric tests as appropriate 
(median test, Wilcoxon Rank Sum test). Crude (cOR) and maternal-age adjusted odds ratios 
(aOR) with 95% confidence intervals (CI) were calculated using conditional logistic 
regression and stratified analyses to evaluate maternal age stratum specific estimates. 
Analyses were conducted in SAS 9.1 (SAS Institute, Cary, NC, 2002-3).
Results
Of 113 eligible pregnant women (34 cases; 81 controls) 99 (86%) participated:33 (97.1%) 
cases and 66 (81.5%) controls. Gestational age at enrollment was on average 27.3 weeks 
(range 16-37 weeks) for cases and 27.7 weeks (range 18-38.2 weeks) for controls.
Cases were significantly more likely to be younger, less educated, smoke cigarettes, report a 
previous STI, and among those with a previous pregnancy, report a different partner with 
their current pregnancy than the most recent pregnancy (Table 1). Compared to controls, 
cases reported a significantly lower median age at sexual debut (defined as first reported age 
at vaginal intercourse) (p=0.0002) and a greater number of sexual partners since their debut 
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(p=0.058) (Figure 1a, 1b). Both the number of sexual partners since becoming sexually 
active (sexual debut) and a change in partner from the previous pregnancy were associated 
with an increased risk for gastroschisis (Table 2). Among women <25 years of age, cases 
reported more sexual partners than controls (p=0.006) compared to women ≥25 (p=.66). 
When specifically queried about previous STI diagnoses, cases more often reported a prior 
CT infection (5 [15.2%] vs. 1 [1.5%]), genital herpes (1 [3.0%] vs. 1 [1.5%]), and gonorrhea 
(1 [3%] vs. 0%) (any self-reported STI: aOR=6.7, 95%CI: 0.7, 58.8). Among women 
reporting illicit drug use during the periconceptional period, only marijuana use was 
reported.
All participating cases and controls consented to have their medical records reviewed. 
Evidence of a negative screening NAAT for chlamydia and gonorrhea at the first prenatal 
visit was documented in the prenatal medical records for 19 (57.6%) cases and 37 (56%) 
controls. The remaining medical records either did not document that a screening NAAT 
was performed (10 [30.3%] cases; 28 [42.4%] controls), or if performed, did not document 
the results (4 [12.1%] cases; 1 [1.5%] controls). No medical records included the screening 
method used to determine a negative or positive screen.
Anti-CT Antibody Detection by CT EB- ELISA
Overall, 62 (62.6%) participants were CT seropositive by IgG1 and 25 (25.3%) by IgG3; 15 
(15.2%) were CT positive by both IgG1 and IgG3. Anti-CT IgG1 seropositivity was not 
significantly associated with gastroschisis (Table 3). Anti-CT IgG3 seropositivity (39.4% of 
cases and 18.2% of controls) was associated with greater than a three-fold increased risk for 
gastroschisis (cOR=3.4, 95%CI: 1.2, 9.8; aOR=3.9, 95%CI: 1.1, 13.2) (Table 3). No 
association was observed for IgG1 seropositivity among women <25 (OR=0.8, 95%CI 0.28, 
2.5; p=0.84) or ≥25 years of age (OR=0.8, 95%CI 0.2, 4.2; p=0.81). Whereas, the risk of 
gastroschisis for women <25 years of age was increased among those with IgG3 
seropositivity (cOR=3.9, 95%CI 1.0, 14.6; p=0.02) compared to women ≥25 years of age 
(cOR=2.7, 95%CI 0.5, 14.7; p=0.24) (data not shown). The magnitude of the anti-CT IgG1 
response detected was lower in cases than controls (median OD, 0.11 vs. 0.17; p=0.118) 
(Figure 2a), and among participants IgG1 seropositive, the magnitude of the response was 
lower in cases compared to controls (median OD 0.22 vs. 0.49; p=0.013) (Figures 2b). In 
contrast, the magnitude of the anti-CT IgG3 response detected did not differ between cases 
and controls (median OD 0.05 vs. 0.04; p=0.135) (Figure 3a),and among those who were 
IgG3 seropositive the magnitude of response also did not significantly differ in cases 
compared to controls (median OD, 0.16 vs. 0.13; p=0.73) (Figure 3b).
Discussion
The findings show that maternal anti-CT IgG3 seropositivity was associated with a 3.9-fold 
increased risk for gastroschisis in the offspring. A study by Geisler et al.13 demonstrated that 
anti-CT IgG1 and IgG3 comprised the predominant anti-CT serum antibody responses. It is 
believed that IgG3 is involved early in response to infection and then is short-lived with 
IgG1 emerging as the major effector in eradicating infection.15 Geisler et al.13 reported 
some decline in the magnitude of the IgG3 response within 6 months of chlamydia 
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treatment. It is plausible that detection of anti-CT IgG3 in this cohort of pregnant women 
suggests a more recent CT exposure, potentially in the periconceptional period where CT 
infection could contribute to the development of gastroschisis.
The mechanism by which CT infection could lead to gastroschisis is not known. One 
mechanism might be proinflammatory cytokines induced by chlamydia impairing normal 
abdominal wall development. CT infections can lead to salpingitis, infertility, ectopic 
pregnancy, reactive arthritis, and perihepatitis.16 The innate and adaptive immune response 
induces systemic inflammation leading to cytokine production which has the potential to 
damage cells.
The sexual history of participants was consistent with behaviors that are known to increase 
the likelihood of acquiring an STI.11,17,18 Compared to controls, cases as a group were 
sexually active at a younger age, had more sexual partners, and more frequently reported a 
change in partner from their previous pregnancy. Sexually active adolescents and young 
women are much more susceptible to sexually transmitted infections. Unlike the squamous 
cells in the cervical epithelium of adult females, the genital tracts of adolescent and young 
women are lined by immature undifferentiated columnar epithelial cells.17 This immature 
epithelium is thought to be more susceptible to pathogens and is the preferred site for C. 
trachomatis and Neisseria gonorrhea.17 In epidemiologic studies, young maternal age has 
been the strongest and most consistent risk factor for gastroschisis.1 The mechanism 
underlying this association is not understood but could be related to the combination of 
exposure (increased risk for sexually transmitted infections due to more risky behaviors) and 
susceptibility (the biology of the reproductive tract). Eight (24.2%) cases and 19 (28.8%) 
controls did not have any evidence (no IgG1 or IgG3 seropositivity) of prior CT infection, 
suggesting that other infections or environmental exposures are responsible for gastroschisis.
The study had several strengths. Participation in the study for both case and control women 
was high, demonstrating that women are willing to participate in a research study during 
pregnancy despite their new diagnosis of a fetal anomaly. We used a highly sensitive 
serologic test, CT EB ELISA, to maximize the detection of a prior known or subclinical CT 
infection; our study also confirmed that CT EB ELISA detects chlamydia antibodies more 
often than commercially available assays. The use of a sensitive test is crucial as it helps 
reduce (or eliminate) the potential for exposure misclassification which may influence the 
accuracy of detected associations between CT infection and risk for gastroschisis. This study 
was the first step to determine whether CT seropositivity increases the risk for gastroschisis. 
Whether it is the pathogen or the inflammatory response as a result of the pathogen requires 
further research. We also found that more than 40% of prenatal medical records lacked 
detailed information on whether screening for STIs was conducted during the first prenatal 
visit or if conducted, the results were not listed. There is also the possibility that some of the 
negative screens were false negatives since the immune system can clear a subclinical local 
chlamydia infection.11
The findings from this study must be interpreted in the context of its limitations. An 
important limitation is that this was an exploratory pilot study to investigate the feasibility 
for the methodology with a small sample of eligible cases. The focus on prenatally 
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diagnosed cases meant that we would have missed a woman whose affected pregnancy was 
not prenatally diagnosed. Among Utah residents, approximately 90% of cases are prenatally 
diagnosed and referred to the University of Utah for delivery. Only a small number of 
women (n=3 or 10%) would not have had the opportunity to participate in the study because 
they were not prenatally diagnosed with gastroschisis. The gestational age at enrollment was 
later than anticipated. We estimated initially that the majority of the diagnoses and 
enrollment would have occurred at 18 to 20 weeks gestation. In reality, the average 
gestational-age at enrollment was 27 weeks, which may have influenced our ability to detect 
active chlamydia infection by NAAT. Community obstetric providers may have referred 
their patients for a MFDC confirmation ultrasound weeks after the initial ultrasound 
diagnosing a gastroschisis. Another limitation of the study was that we were not able to test 
for other pathogens known to cause STIs. However, serum samples were banked for future 
studies on additional viral or bacterial pathogens. Finally, the questionnaire was 
administered during pregnancy, soon after the prenatal diagnosis of a fetal abnormality 
(gastroschisis) and 76% of the cases were less than 25 years of age compared to 44% of 
controls. Young women may feel more comfortable, in general, answering questions about 
their sexual encounters, potentially inflating the findings on sexual history.
GU infections, and CT infections specifically, could represent an intermediate step between 
risky sexual behaviors and increased risk for gastroschisis: these behaviors increase the 
likelihood to acquire one or more sexually transmitted infections, which in turn may be 
particularly harmful in pregnancies of young women because of the particular susceptibility 
of their reproductive system. Finding an increased risk for gastroschisis among women with 
evidence of a recent CT infection is the first step in understanding the association with this 
pathogen and the host's subsequent systemic inflammatory response. CT has the ability to 
induce a systemic inflammatory response, the magnitude of which may differ in cases 
compared to controls as a result of the individual's immunogenetic determinants. Future 
research should include evaluation of the influence of CT-specific cellular immune 
responses on gastroschisis risk. In addition, this study underscores the important role of 
biomarker-based studies in birth defect epidemiology. Because the majority of CT infections 
in women are subclinical, association can be easily missed or distorted if appropriate 
biomarkers such as serum antibodies are not used, and associations are exclusively based on 
self-reports of such challenging exposures.
Conclusion
Anti-CT IgG3 seropositivity was associated with more than a 3-fold risk for gastroschisis, 
which in combination with the association of risky sexual behavior suggests recent CT 
infection around or shortly after conception increases gastroschisis risk.
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Figure 1. 
a: Maternal age at sexual debut among cases (n=33) and controls (n=66)
b: Number of sexual partners by case (n=32) and control (n=66) status
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Figure 2. 
a: Anti-Chlamydia trachomatis IgG1 OD405 reading by case (n=33) and control (n=66) 
status
b: Seropositive (≥ 0.1 OD405) anti-Chlamydia trachomatis IgG1 by case (n=20) and control 
(n=42) status
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Figure 3. 
a: Anti-Chlamydia trachomatis IgG3 OD405 reading by case (n=33) and control (n=66) 
status
b: Seropositive (≥ 0.08 OD405) anti-Chlamydia trachomatis IgG3 by case (n=13) and control 
(n=12) status
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Table 2
Association for sexual history of case and control women
Number of sexual partnersa Case Control cOR (95%CI)
1 8 32 Ref
2 3 6 2.3 (0.5, 12.0)
≥3 21 28 3.3 (1.2, 9.4)
Previous pregnancy with same partner
Yes 6 32 ref
No 10 5 3.6 (0.9, 13.9)
aOne case – did not report number of sexual partners
Abbreviations: cOR, crude odds ratio; 95%CI, 95% confidence interval
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Table 3
Association for anti-chlamydia specific antibodies and gastroschisis
Anti-Chlamydia IgG1 Seropositive Anti-Chlamydia IgG3 Seropositive
Yes n (%) No n (%) Yes n (%) No n (%)
Cases 20 (60.6%) 13 (39.4%) 13 (39.4%) 20 (60.5%)
Controls 42 (63.6%) 24 (36.4%) 12 (18.2%) 54 (81.8%)
cOR = 0.9 (95% CI: 0.4, 2.0)
aOR = 0.8 (95% CI: 0.3, 2.0)
cOR = 3.4 (95%CI: 1.2, 9.8)
aOR = 3.9 (95% CI: 1.1, 13.2)
Abbreviations:
cOR, crude odds ratio; 95%CI, 95% confidence interval
aOR, odds ratio, adjusted for maternal age
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